

# OUR PIPELINE

Takeda Oncology is working to discover and develop innovative new therapies that will make a difference in patients' lives.

The molecules in our development pipeline are ordered by their phase in the clinical development process, and within each phase molecules are ordered alphabetically. Phase 1 trials are conducted to determine proper dosing, while Phase 2 and 3 Studies determine the efficacy, side effects and safety of the therapies being researched.

Certain molecules may be under study for more than one disease area. Click on the arrows to learn more about each one.

PROGRAM	PHASE 1	PHASE 2	PHASE 3
<b>BRENTUXIMAB VEDOTIN<sup>1</sup></b>	●	●	●
<b>DESCRIPTION</b> CD30 Antibody Drug Conjugate	<b>DISEASE(S) UNDER INVESTIGATION</b> Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Mature T-Cell Lymphoma, Anaplastic Large Cell Lymphoma		
<b>BRIGATINIB</b>	●	●	●
<b>DESCRIPTION</b> ALK Inhibitor	<b>DISEASE(S) UNDER INVESTIGATION</b> Non-small Cell Lung Cancer		
<b>IXAZOMIB</b>	●	●	●
<b>DESCRIPTION</b> Proteasome Inhibitor	<b>DISEASE(S) UNDER INVESTIGATION</b> Multiple Myeloma, Amyloidosis		

PROGRAM	PHASE 1	PHASE 2	PHASE 3
---------	---------	---------	---------

**LEUPRORELIN ACETATE<sup>2</sup>**



**DESCRIPTION**  
LH-RH Agonist

**DISEASE(S) UNDER INVESTIGATION**  
Prostate Cancer, Breast Cancer, new formulation

**PANITUMUMAB<sup>3</sup>**



**DESCRIPTION**  
Anti-EGFR Antibody

**DISEASE(S) UNDER INVESTIGATION**  
Colorectal Cancer

**PEVONEDISTAT**



**DESCRIPTION**  
Nedd8-Activating Enzyme Inhibitor

**DISEASE(S) UNDER INVESTIGATION**  
High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low-Blast Acute Myelogenous Leukemia

**PEVONEDISTAT**



**DESCRIPTION**  
Nedd8-Activating Enzyme Inhibitor

**DISEASE(S) UNDER INVESTIGATION**  
Solid Tumors

PROGRAM	PHASE 1	PHASE 2	PHASE 3
---------	---------	---------	---------

**PONATINIB<sup>4</sup>**



**DESCRIPTION**  
BCR-ABL Inhibitor

**DISEASE(S) UNDER INVESTIGATION**  
Chronic Myeloid Leukemia

**PONATINIB<sup>4</sup>**



**DESCRIPTION**  
BCR-ABL Inhibitor

**DISEASE(S) UNDER INVESTIGATION**  
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

**SAPANISERTIB (TAK-228)**



**DESCRIPTION**  
TORC1/TORC2 Inhibitor

**DISEASE(S) UNDER INVESTIGATION**  
Breast Cancer, Renal Cell Carcinoma, Endometrial Cancer

**TAK-117**



**DESCRIPTION**  
PI3K Alpha Inhibitor

**DISEASE(S) UNDER INVESTIGATION**  
Renal Cell Carcinoma

PROGRAM

PHASE 1

PHASE 2

PHASE 3

TAK-659



**DESCRIPTION**

SYK/FLT-3 Inhibitor

**DISEASE(S) UNDER INVESTIGATION**

Lymphoma, Acute Myelogenous Leukemia

TAK-659



**DESCRIPTION**

SYK/FLT-3 Inhibitor

**DISEASE(S) UNDER INVESTIGATION**

Solid Tumors

TAK-931



**DESCRIPTION**

CDC7 Inhibitor

**DISEASE(S) UNDER INVESTIGATION**

Pancreatic Cancer, Colorectal Cancer

VEDOLIZUMAB



**DESCRIPTION**

Anti- $\alpha$ 4 $\beta$ 7 Antibody

**DISEASE(S) UNDER INVESTIGATION**

Graft versus Host Disease

PROGRAM

PHASE 1

PHASE 2

PHASE 3

TAK-243



**DESCRIPTION**

Ubiquitin-Activating Enzyme Inhibitor

**DISEASE(S) UNDER INVESTIGATION**

Solid Tumors

TAK-522 (*XMT-1522*)<sup>5</sup>



**DESCRIPTION**

HER2 Dolaflexin Antibody Drug Conjugate

**DISEASE(S) UNDER INVESTIGATION**

Breast Cancer

TAK-573



**DESCRIPTION**

CD38-targeted IgG4 fused with attenuated IFN $\alpha$

**DISEASE(S) UNDER INVESTIGATION**

Multiple Myeloma

TAK-580



**DESCRIPTION**

Pan-Raf Inhibitor

**DISEASE(S) UNDER INVESTIGATION**

Solid Tumors

PROGRAM	PHASE 1	PHASE 2	PHASE 3
---------	---------	---------	---------

**TAK-788 (AP32788)**



<b>DESCRIPTION</b> EGFR/HER2 Inhibitor	<b>DISEASE(S) UNDER INVESTIGATION</b> Non-small Cell Lung Cancer
---	---

**CABOZANTINIB<sup>2</sup>**

Development in Preparation

<b>DESCRIPTION</b> MET, VEGF, AXL and RET Inhibitor	<b>DISEASE(S) UNDER INVESTIGATION</b> Renal Cell Carcinoma
--	---

**NIRAPARIB<sup>6</sup>**

Development in Preparation

<b>DESCRIPTION</b> PARP Inhibitor	<b>DISEASE(S) UNDER INVESTIGATION</b> Solid Tumors
--------------------------------------	---

Last Updated 2017-10-31

All programs have Global Development Rights unless otherwise noted.

1 Brentuximab vedotin is co-developed by Takeda and Seattle Genetics, Inc. 2 Japan Only. 3 Japan Only. In-Licensed. 4 Takeda shares development rights with Incyte (Europe, Turkey and Israel) and Otsuka (Asia Pacific territories). 5 Ex-US, Ex-Canada. TAK-522 (XMT-1522) is co-developed by Takeda and Mersana Therapeutics, Inc. 6 Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia.



ONCOLOGY

©2018 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.  
 All rights reserved. 04/18